Kantar Health Blog

  • Wear it … but only if it fits

    by Mark Sales | Jul 17, 2015
    Mark Sales
    Being on the cutting edge of technology is a great thing. It’s an exciting thing. But remember that the end user experience is the most important part of developing any product or app.
    Continue Reading > | Go comment! | Share
  • Debbie Warner
    Value was an overarching theme at ASCO 2015 and has been a topic of ongoing focus, as have been the burgeoning pipeline of immunotherapy agents, with the recently launched PD-1 inhibitors, Opdivo® (nivolumab, Bristol Myers Squibb) and Keytruda® (pembrolizumab, Merck), being the highlights of ASCO 2015. Presenter Leonard Saltz, M.D. of Memorial Sloan Kettering praised the clinical value of an Opdivo + Keytruda combination as being “truly, truly remarkable,” but he added that with the combination costing nearly $300,000 (if continued for 11 months) “these drugs cost too much –unsustainable.” While Dr. Saltz is an unabashed critic of cancer drug prices, $300,000 would give most people pause.
    Continue Reading > | Go comment! | Share
  • Mark Sales
    If you are still focused on whether a customer experience program will bring value to your organization, you are missing the point.
    Continue Reading > | Go comment! | Share
  • Crowd surfing: Competition in myeloma continues to rage on

    by Stephanie Hawthorne | Jun 2, 2015
    Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- The number of agents available to treat relapsed/refractory myeloma has expanded rapidly over the past three years, with the launch of next-generation proteasome inhibitor Kyprolis® (carfilzomib, Onyx /Amgen, accelerated FDA approval July 2012) and the next-generation immunomodulator Pomalyst® (pomalidomide, Celgene, FDA approved February 2013) as monotherapies, and the HDAC inhibitor Farydak® (panobinostat, Novartis, accelerated FDA approval February 2015) for use in combination with bortezomib + dexamethasone (VelDex). These three agents add to the long-established standards of care, Velcade® (bortezomib, Millennium/Takeda) and Revlimid® (lenalidomide, Celgene), which are used in both newly diagnosed and relapsed/refractory patients.
    Continue Reading > | Go comment! | Share
  • Arnold DuBell
    Oncology Conference Insight: ASCO 2015 --- Immunotherapy has dominated the conversation in oncology for the past several years, and the excitement still hasn’t waned at all - in fact it continues to grow. New drugs have entered development in this space, new mechanisms of action have emerged, and new tumor types have entered the focus of our attention. We have previously seen various level of evidence to support the activity of checkpoint inhibitors in melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, breast cancer, gastric cancer, head and neck cancer, and Hodgkin’s lymphoma. At this year’s annual meeting of the American Society of Clinical Oncology, we observed first reports of the activity of several PD-1 and PD-L1 inhibitors in multiple new tumor indications, adding to the growing body of evidence that suggests immunotherapy is closely approaching panacea status.
    Continue Reading > | Go comment! | Share